BIOCON vs THEMISMED: Stock Comparison

Biocon Limited vs Themis Medicare Limited

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Biocon Limited is the larger company by market capitalisation. Biocon Limited shows a lower P/E, a higher ROE and lower leverage, while Themis Medicare Limited shows a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biocon Limited and Themis Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOCON is more favourable on 8 of 13 scored metrics and THEMISMED on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BIOCON is the larger company
₹70,989 Cr vs ₹1,004 Cr
P/E Ratio
BIOCON has a lower P/E
185.25x vs 938.33x
P/B Ratio
BIOCON has a lower P/B
2.1x vs 2.6x
EPS
BIOCON has higher earnings per share
₹2.86 vs ₹0.12
Dividend Yield
THEMISMED has a higher dividend yield
0.43% vs 0.11%
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs 2.3%
EPS Growth (TTM YoY)
THEMISMED has faster EPS growth
0% vs -72.5%
Qtr Sales Growth
THEMISMED has stronger quarterly sales growth
6.74% vs 2.25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOCONTHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOCONTHEMISMED
Live Price₹437.75₹108.4
Day Change-0.58%-3.52%
Volume51.58 L70,771
52-Week High₹447.15₹148
52-Week Low₹331₹64.95
Distance from 52W High-2.1%-26.76%

Valuation

MetricBIOCONTHEMISMED
Market Cap₹70,989 Cr₹1,004 Cr
P/E Ratio185.25x938.33x
P/B Ratio2.1x2.6x
EPS₹2.86₹0.12
Book Value₹210.14₹43.06
Dividend Yield0.11%0.43%

Growth

MetricBIOCONTHEMISMED
Revenue Growth (TTM YoY)2.3%6.7%
EPS Growth (TTM YoY)-72.5%0%
Qtr Sales Growth2.25%6.74%
Qtr Profit Growth-62%192%

Profitability & Leverage

MetricBIOCONTHEMISMED
ROE1.4%0.29%
ROCE3.75%2.74%
Net Margin2.29%0.33%
Operating Margin20.4%-2.9%
Debt to Equity0.45x25.11x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOCONTHEMISMED
Promoter Holding29.73% 0.17 pp57.5%
FII Holding8.16% 0.64 pp0.11% 0.06 pp
DII Holding23.37% 0.7 pp0.01%
Public Holding23.74% 0.33 pp32.78% 0.05 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biocon Limited and Themis Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.